Daniel Bowles
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Agents | 30 | 2024 | 2051 | 3.580 |
Why?
| Head and Neck Neoplasms | 16 | 2023 | 533 | 3.090 |
Why?
| Salivary Gland Neoplasms | 8 | 2023 | 33 | 3.060 |
Why?
| Carcinoma, Squamous Cell | 14 | 2019 | 620 | 2.390 |
Why?
| Protein Kinase Inhibitors | 14 | 2024 | 872 | 2.320 |
Why?
| Pyridines | 11 | 2024 | 475 | 2.140 |
Why?
| Thyroid Neoplasms | 9 | 2024 | 309 | 2.030 |
Why?
| Neoplasm Recurrence, Local | 7 | 2023 | 958 | 1.780 |
Why?
| Molecular Targeted Therapy | 7 | 2021 | 385 | 1.770 |
Why?
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 1045 | 1.760 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 1559 | 1.660 |
Why?
| Neoplasms | 20 | 2024 | 2464 | 1.620 |
Why?
| Protein-Tyrosine Kinases | 4 | 2021 | 430 | 1.520 |
Why?
| Lung Neoplasms | 10 | 2023 | 2328 | 1.450 |
Why?
| Anilides | 6 | 2024 | 73 | 1.440 |
Why?
| Gonanes | 7 | 2016 | 27 | 1.420 |
Why?
| Proto-Oncogene Proteins | 6 | 2021 | 634 | 1.380 |
Why?
| Biomarkers, Tumor | 8 | 2020 | 1181 | 1.340 |
Why?
| Thyroid Carcinoma, Anaplastic | 3 | 2020 | 35 | 1.340 |
Why?
| Cetuximab | 7 | 2018 | 93 | 1.330 |
Why?
| Adenocarcinoma | 7 | 2024 | 888 | 1.310 |
Why?
| Phosphatidylinositol 3-Kinases | 8 | 2017 | 357 | 0.870 |
Why?
| Mutation | 13 | 2024 | 3689 | 0.820 |
Why?
| Carcinoma | 3 | 2019 | 214 | 0.760 |
Why?
| Neoplasm Staging | 15 | 2019 | 1290 | 0.740 |
Why?
| Phytotherapy | 2 | 2012 | 75 | 0.730 |
Why?
| Drugs, Investigational | 2 | 2011 | 32 | 0.730 |
Why?
| Cisplatin | 6 | 2024 | 297 | 0.720 |
Why?
| Pyrazoles | 5 | 2023 | 404 | 0.680 |
Why?
| Disease-Free Survival | 10 | 2017 | 647 | 0.670 |
Why?
| Neoplasms, Second Primary | 1 | 2021 | 108 | 0.660 |
Why?
| Papillomaviridae | 4 | 2019 | 113 | 0.660 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2018 | 175 | 0.660 |
Why?
| Quinolines | 5 | 2024 | 153 | 0.650 |
Why?
| Carcinoma, Renal Cell | 3 | 2017 | 179 | 0.650 |
Why?
| Taxoids | 3 | 2015 | 95 | 0.650 |
Why?
| Humans | 89 | 2024 | 128418 | 0.640 |
Why?
| Hedgehog Proteins | 3 | 2015 | 187 | 0.630 |
Why?
| Drug Resistance, Neoplasm | 8 | 2024 | 749 | 0.620 |
Why?
| Marijuana Smoking | 2 | 2012 | 239 | 0.590 |
Why?
| Tumor Suppressor Proteins | 2 | 2018 | 313 | 0.590 |
Why?
| Middle Aged | 43 | 2024 | 30889 | 0.590 |
Why?
| Pyrimidines | 5 | 2023 | 445 | 0.590 |
Why?
| Colorectal Neoplasms | 2 | 2016 | 746 | 0.570 |
Why?
| Aged | 39 | 2024 | 21953 | 0.570 |
Why?
| Kidney Neoplasms | 3 | 2017 | 349 | 0.560 |
Why?
| Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.550 |
Why?
| Ubiquitin Thiolesterase | 1 | 2017 | 42 | 0.540 |
Why?
| Carcinoma, Transitional Cell | 4 | 2017 | 60 | 0.530 |
Why?
| Carcinoma, Ductal | 1 | 2016 | 11 | 0.530 |
Why?
| Adenoma, Pleomorphic | 1 | 2016 | 9 | 0.530 |
Why?
| Cannabinoids | 2 | 2024 | 129 | 0.520 |
Why?
| Sulfones | 2 | 2014 | 108 | 0.520 |
Why?
| Gene Rearrangement | 2 | 2018 | 146 | 0.520 |
Why?
| Glycine | 2 | 2014 | 164 | 0.510 |
Why?
| Maximum Tolerated Dose | 5 | 2017 | 192 | 0.480 |
Why?
| Enzyme Inhibitors | 3 | 2014 | 809 | 0.450 |
Why?
| Drug Interactions | 6 | 2017 | 357 | 0.440 |
Why?
| Melanoma | 1 | 2021 | 752 | 0.440 |
Why?
| Pyrroles | 1 | 2014 | 191 | 0.430 |
Why?
| Male | 44 | 2024 | 62858 | 0.430 |
Why?
| Signal Transduction | 8 | 2018 | 4826 | 0.430 |
Why?
| Iodine Radioisotopes | 5 | 2024 | 142 | 0.420 |
Why?
| Gene Fusion | 3 | 2023 | 24 | 0.420 |
Why?
| Phenylurea Compounds | 4 | 2024 | 89 | 0.420 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2012 | 221 | 0.410 |
Why?
| Genetic Variation | 1 | 2018 | 933 | 0.410 |
Why?
| Female | 45 | 2024 | 68154 | 0.410 |
Why?
| Lymph Nodes | 4 | 2017 | 466 | 0.400 |
Why?
| Indazoles | 3 | 2019 | 64 | 0.400 |
Why?
| Aged, 80 and over | 15 | 2024 | 7033 | 0.390 |
Why?
| Treatment Outcome | 15 | 2024 | 10152 | 0.390 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 4 | 2017 | 81 | 0.380 |
Why?
| Quinazolines | 1 | 2013 | 243 | 0.380 |
Why?
| Antibodies, Monoclonal, Humanized | 4 | 2024 | 755 | 0.380 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 111 | 0.370 |
Why?
| Neoplasm Metastasis | 6 | 2021 | 608 | 0.350 |
Why?
| Proto-Oncogene Proteins c-ret | 4 | 2023 | 29 | 0.340 |
Why?
| Adult | 26 | 2024 | 35300 | 0.340 |
Why?
| Prognosis | 9 | 2021 | 3772 | 0.310 |
Why?
| Papillomavirus Infections | 3 | 2022 | 290 | 0.300 |
Why?
| ErbB Receptors | 4 | 2017 | 601 | 0.300 |
Why?
| Pharmacogenomic Variants | 2 | 2018 | 35 | 0.290 |
Why?
| Nitriles | 2 | 2022 | 157 | 0.280 |
Why?
| Urologic Neoplasms | 2 | 2017 | 25 | 0.270 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2024 | 814 | 0.270 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2007 | 82 | 0.270 |
Why?
| Platinum | 2 | 2024 | 44 | 0.270 |
Why?
| Mitoxantrone | 1 | 2006 | 14 | 0.270 |
Why?
| Enterobacter | 1 | 2006 | 7 | 0.260 |
Why?
| Tooth Diseases | 1 | 2006 | 13 | 0.260 |
Why?
| Gene Expression Profiling | 5 | 2018 | 1688 | 0.250 |
Why?
| Esophageal and Gastric Varices | 1 | 2006 | 36 | 0.250 |
Why?
| Enterobacteriaceae Infections | 1 | 2006 | 36 | 0.250 |
Why?
| Benzamides | 2 | 2019 | 194 | 0.250 |
Why?
| Animals | 16 | 2024 | 34479 | 0.250 |
Why?
| Salivary Glands | 2 | 2023 | 29 | 0.250 |
Why?
| Oropharyngeal Neoplasms | 2 | 2016 | 48 | 0.250 |
Why?
| Acute Kidney Injury | 3 | 2018 | 773 | 0.250 |
Why?
| Chemoradiotherapy | 4 | 2020 | 209 | 0.240 |
Why?
| Clinical Trials as Topic | 3 | 2018 | 993 | 0.240 |
Why?
| Registries | 2 | 2016 | 1877 | 0.240 |
Why?
| Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.240 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 214 | 0.230 |
Why?
| Cannabis | 1 | 2011 | 429 | 0.230 |
Why?
| Immunotherapy | 2 | 2023 | 587 | 0.230 |
Why?
| Receptors, Estrogen | 1 | 2007 | 424 | 0.230 |
Why?
| Antiemetics | 1 | 2024 | 39 | 0.230 |
Why?
| Urinary Bladder Neoplasms | 2 | 2017 | 226 | 0.220 |
Why?
| Models, Biological | 3 | 2024 | 1691 | 0.220 |
Why?
| Liver Cirrhosis | 1 | 2006 | 275 | 0.220 |
Why?
| Bacteremia | 1 | 2006 | 190 | 0.220 |
Why?
| Carcinoma, Adenoid Cystic | 1 | 2023 | 17 | 0.220 |
Why?
| Combined Modality Therapy | 4 | 2018 | 1204 | 0.220 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1351 | 0.220 |
Why?
| Administration, Oral | 3 | 2014 | 754 | 0.210 |
Why?
| Phenylthiohydantoin | 1 | 2022 | 44 | 0.200 |
Why?
| Survival Rate | 5 | 2021 | 1869 | 0.190 |
Why?
| Medical Marijuana | 1 | 2024 | 107 | 0.190 |
Why?
| Referral and Consultation | 1 | 2007 | 727 | 0.190 |
Why?
| Breast Neoplasms | 2 | 2019 | 2132 | 0.190 |
Why?
| Drug Evaluation, Preclinical | 2 | 2013 | 168 | 0.190 |
Why?
| Chemotherapy, Adjuvant | 3 | 2017 | 376 | 0.190 |
Why?
| Radiation Pneumonitis | 1 | 2021 | 28 | 0.190 |
Why?
| Survival Analysis | 4 | 2020 | 1263 | 0.190 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2021 | 32 | 0.180 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2016 | 380 | 0.180 |
Why?
| Adrenal Cortex Neoplasms | 1 | 2021 | 60 | 0.170 |
Why?
| Adrenocortical Carcinoma | 1 | 2021 | 63 | 0.170 |
Why?
| Disease Susceptibility | 2 | 2020 | 331 | 0.170 |
Why?
| SEER Program | 1 | 2021 | 206 | 0.170 |
Why?
| Cystectomy | 2 | 2017 | 38 | 0.170 |
Why?
| Gene Expression | 2 | 2015 | 1456 | 0.170 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 16 | 0.170 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 853 | 0.170 |
Why?
| United States | 8 | 2021 | 13830 | 0.160 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2006 | 591 | 0.160 |
Why?
| Radiosurgery | 1 | 2022 | 318 | 0.160 |
Why?
| DNA Mutational Analysis | 2 | 2018 | 384 | 0.160 |
Why?
| Tracheal Neoplasms | 1 | 2019 | 10 | 0.160 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 84 | 0.160 |
Why?
| Lymph Node Excision | 2 | 2017 | 165 | 0.160 |
Why?
| Smad4 Protein | 1 | 2019 | 37 | 0.160 |
Why?
| Prostatic Neoplasms | 1 | 2006 | 1011 | 0.150 |
Why?
| Genetic Heterogeneity | 1 | 2019 | 57 | 0.150 |
Why?
| Benzazepines | 1 | 2018 | 40 | 0.150 |
Why?
| Genomics | 3 | 2021 | 715 | 0.150 |
Why?
| Alphapapillomavirus | 2 | 2016 | 40 | 0.150 |
Why?
| Palliative Care | 2 | 2018 | 713 | 0.150 |
Why?
| Disease Management | 2 | 2020 | 587 | 0.150 |
Why?
| Risk | 1 | 2021 | 853 | 0.150 |
Why?
| Chromosome Aberrations | 1 | 2019 | 148 | 0.150 |
Why?
| DNA Mismatch Repair | 1 | 2018 | 47 | 0.150 |
Why?
| Receptor, ErbB-2 | 2 | 2019 | 325 | 0.150 |
Why?
| Tissue Fixation | 1 | 2017 | 33 | 0.140 |
Why?
| Paraffin Embedding | 1 | 2017 | 27 | 0.140 |
Why?
| Oncogenes | 1 | 2018 | 109 | 0.140 |
Why?
| Erlotinib Hydrochloride | 1 | 2017 | 69 | 0.140 |
Why?
| Smokers | 1 | 2018 | 137 | 0.140 |
Why?
| Formaldehyde | 1 | 2017 | 57 | 0.140 |
Why?
| Nasopharyngeal Neoplasms | 1 | 2017 | 16 | 0.140 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.140 |
Why?
| Gene Deletion | 1 | 2019 | 370 | 0.140 |
Why?
| Health Services Needs and Demand | 1 | 2019 | 264 | 0.140 |
Why?
| Neoplasm Grading | 1 | 2018 | 283 | 0.140 |
Why?
| DNA, Neoplasm | 1 | 2017 | 159 | 0.140 |
Why?
| Induction Chemotherapy | 1 | 2017 | 70 | 0.130 |
Why?
| Gene Frequency | 1 | 2018 | 504 | 0.130 |
Why?
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 41 | 0.130 |
Why?
| Salivary Ducts | 1 | 2016 | 2 | 0.130 |
Why?
| Hospice and Palliative Care Nursing | 1 | 2018 | 74 | 0.130 |
Why?
| Laryngeal Neoplasms | 1 | 2016 | 29 | 0.130 |
Why?
| Patient Navigation | 1 | 2018 | 79 | 0.130 |
Why?
| Prospective Studies | 7 | 2024 | 7036 | 0.130 |
Why?
| Carboplatin | 1 | 2016 | 140 | 0.130 |
Why?
| Muscle, Smooth | 1 | 2017 | 145 | 0.130 |
Why?
| Nomograms | 1 | 2016 | 47 | 0.130 |
Why?
| Young Adult | 5 | 2021 | 12312 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 1936 | 0.130 |
Why?
| Population Surveillance | 1 | 2019 | 427 | 0.130 |
Why?
| Database Management Systems | 1 | 2016 | 48 | 0.130 |
Why?
| Disease Progression | 4 | 2018 | 2602 | 0.130 |
Why?
| Retrospective Studies | 8 | 2021 | 14454 | 0.130 |
Why?
| Computational Biology | 2 | 2018 | 598 | 0.130 |
Why?
| Incidence | 2 | 2019 | 2616 | 0.120 |
Why?
| Angiopoietin-1 | 1 | 2015 | 11 | 0.120 |
Why?
| Angiopoietin-2 | 1 | 2015 | 15 | 0.120 |
Why?
| Radiotherapy | 1 | 2016 | 185 | 0.120 |
Why?
| Bone Neoplasms | 1 | 2017 | 229 | 0.120 |
Why?
| Genetic Testing | 1 | 2018 | 428 | 0.120 |
Why?
| Zinc Finger Protein GLI1 | 1 | 2014 | 24 | 0.120 |
Why?
| Retreatment | 1 | 2014 | 69 | 0.120 |
Why?
| Hospice Care | 1 | 2018 | 198 | 0.120 |
Why?
| Piperazines | 2 | 2018 | 336 | 0.120 |
Why?
| Neoplasms, Unknown Primary | 1 | 2014 | 13 | 0.110 |
Why?
| Response Evaluation Criteria in Solid Tumors | 1 | 2014 | 17 | 0.110 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 421 | 0.110 |
Why?
| Paclitaxel | 1 | 2015 | 214 | 0.110 |
Why?
| Neoplastic Stem Cells | 1 | 2018 | 386 | 0.110 |
Why?
| Patient Satisfaction | 1 | 2018 | 641 | 0.110 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 484 | 0.110 |
Why?
| Pilot Projects | 2 | 2015 | 1564 | 0.110 |
Why?
| Sulfonamides | 1 | 2017 | 499 | 0.110 |
Why?
| Proportional Hazards Models | 4 | 2017 | 1196 | 0.110 |
Why?
| Promoter Regions, Genetic | 1 | 2018 | 1198 | 0.110 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 19 | 0.110 |
Why?
| ras Proteins | 1 | 2014 | 145 | 0.110 |
Why?
| Cell Cycle Proteins | 2 | 2014 | 577 | 0.100 |
Why?
| PTEN Phosphohydrolase | 1 | 2014 | 157 | 0.100 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 258 | 0.100 |
Why?
| Imatinib Mesylate | 1 | 2012 | 66 | 0.100 |
Why?
| Risk Assessment | 2 | 2019 | 3232 | 0.100 |
Why?
| Dasatinib | 1 | 2012 | 51 | 0.100 |
Why?
| Recombinant Fusion Proteins | 1 | 2015 | 634 | 0.100 |
Why?
| Thiazoles | 1 | 2012 | 115 | 0.100 |
Why?
| Hematopoietic Stem Cells | 1 | 2015 | 378 | 0.100 |
Why?
| Aniline Compounds | 1 | 2012 | 98 | 0.100 |
Why?
| Biomarkers | 3 | 2018 | 3880 | 0.090 |
Why?
| Mice | 7 | 2024 | 16602 | 0.090 |
Why?
| Smoking | 1 | 2019 | 1460 | 0.090 |
Why?
| Biological Availability | 1 | 2011 | 122 | 0.090 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 74 | 0.090 |
Why?
| Imidazoles | 1 | 2012 | 226 | 0.090 |
Why?
| Adolescent | 5 | 2022 | 20179 | 0.090 |
Why?
| Propensity Score | 3 | 2017 | 264 | 0.090 |
Why?
| Carcinoma, Basal Cell | 1 | 2012 | 73 | 0.090 |
Why?
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 26 | 0.090 |
Why?
| Evidence-Based Medicine | 2 | 2012 | 711 | 0.090 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2024 | 500 | 0.090 |
Why?
| Tumor Microenvironment | 1 | 2015 | 623 | 0.090 |
Why?
| Cell Line, Tumor | 4 | 2024 | 3184 | 0.090 |
Why?
| Algorithms | 1 | 2018 | 1618 | 0.090 |
Why?
| Phenotype | 1 | 2018 | 3044 | 0.080 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 2264 | 0.080 |
Why?
| Kidney | 1 | 2017 | 1302 | 0.080 |
Why?
| Adaptation, Psychological | 1 | 2014 | 616 | 0.080 |
Why?
| Brain Neoplasms | 1 | 2018 | 1163 | 0.080 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 89 | 0.080 |
Why?
| Multivariate Analysis | 3 | 2017 | 1484 | 0.080 |
Why?
| Cohort Studies | 4 | 2022 | 5388 | 0.070 |
Why?
| Axilla | 1 | 2007 | 43 | 0.070 |
Why?
| Neoadjuvant Therapy | 2 | 2022 | 381 | 0.070 |
Why?
| Clinical Trials, Phase I as Topic | 2 | 2019 | 50 | 0.070 |
Why?
| RNA, Messenger | 1 | 2014 | 2675 | 0.070 |
Why?
| Caregivers | 1 | 2014 | 810 | 0.070 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2007 | 108 | 0.070 |
Why?
| Mastectomy | 1 | 2007 | 131 | 0.070 |
Why?
| Transcription Factors | 1 | 2014 | 1628 | 0.070 |
Why?
| Ligation | 1 | 2006 | 86 | 0.060 |
Why?
| Stress, Psychological | 1 | 2014 | 1060 | 0.060 |
Why?
| Creatinine | 2 | 2018 | 475 | 0.060 |
Why?
| Pain | 1 | 2011 | 757 | 0.060 |
Why?
| Fatal Outcome | 1 | 2006 | 300 | 0.060 |
Why?
| Lymphatic Metastasis | 2 | 2017 | 318 | 0.060 |
Why?
| Neoplasm Invasiveness | 2 | 2017 | 480 | 0.060 |
Why?
| Double-Blind Method | 2 | 2021 | 1848 | 0.060 |
Why?
| Receptors, Progesterone | 1 | 2007 | 341 | 0.060 |
Why?
| Granisetron | 1 | 2024 | 5 | 0.060 |
Why?
| Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2006 | 119 | 0.060 |
Why?
| Ondansetron | 1 | 2024 | 15 | 0.060 |
Why?
| Risk Factors | 1 | 2019 | 9704 | 0.060 |
Why?
| Isoquinolines | 1 | 2024 | 41 | 0.060 |
Why?
| Skin Neoplasms | 1 | 2012 | 832 | 0.060 |
Why?
| Neoplasm Proteins | 1 | 2007 | 421 | 0.060 |
Why?
| Glomerular Filtration Rate | 2 | 2018 | 681 | 0.060 |
Why?
| Demography | 2 | 2015 | 277 | 0.060 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2023 | 81 | 0.050 |
Why?
| Benzimidazoles | 1 | 2024 | 157 | 0.050 |
Why?
| Recurrence | 2 | 2018 | 996 | 0.050 |
Why?
| Databases, Factual | 2 | 2019 | 1269 | 0.050 |
Why?
| Androgen Antagonists | 1 | 2022 | 79 | 0.050 |
Why?
| Four-Dimensional Computed Tomography | 1 | 2021 | 28 | 0.050 |
Why?
| Quality of Life | 1 | 2013 | 2680 | 0.050 |
Why?
| Immunohistochemistry | 2 | 2018 | 1664 | 0.050 |
Why?
| Pulmonary Ventilation | 1 | 2021 | 76 | 0.050 |
Why?
| Receptors, Androgen | 1 | 2022 | 143 | 0.050 |
Why?
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 123 | 0.050 |
Why?
| Receptor, trkA | 1 | 2019 | 16 | 0.040 |
Why?
| Receptor, trkC | 1 | 2019 | 10 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2019 | 71 | 0.040 |
Why?
| Receptor, trkB | 1 | 2019 | 31 | 0.040 |
Why?
| Trastuzumab | 1 | 2019 | 100 | 0.040 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 163 | 0.040 |
Why?
| Radiotherapy, Image-Guided | 1 | 2018 | 33 | 0.040 |
Why?
| Phthalazines | 1 | 2018 | 40 | 0.040 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2019 | 313 | 0.040 |
Why?
| Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.040 |
Why?
| Glutathione S-Transferase pi | 1 | 2017 | 9 | 0.040 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2017 | 36 | 0.040 |
Why?
| Retroperitoneal Space | 1 | 2017 | 16 | 0.040 |
Why?
| Organic Cation Transport Proteins | 1 | 2017 | 26 | 0.030 |
Why?
| Urinary Diversion | 1 | 2017 | 12 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 2019 | 466 | 0.030 |
Why?
| National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.030 |
Why?
| Margins of Excision | 1 | 2017 | 37 | 0.030 |
Why?
| Social Work | 1 | 2018 | 83 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 930 | 0.030 |
Why?
| Laryngectomy | 1 | 2016 | 14 | 0.030 |
Why?
| Immunophenotyping | 1 | 2018 | 311 | 0.030 |
Why?
| Oncologists | 1 | 2017 | 35 | 0.030 |
Why?
| Hospitals, Veterans | 1 | 2018 | 256 | 0.030 |
Why?
| Kidney Function Tests | 1 | 2017 | 145 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2018 | 3937 | 0.030 |
Why?
| Pelvis | 1 | 2017 | 101 | 0.030 |
Why?
| Carcinogenesis | 1 | 2018 | 209 | 0.030 |
Why?
| Viral Core Proteins | 1 | 2016 | 21 | 0.030 |
Why?
| Cation Transport Proteins | 1 | 2017 | 129 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2006 | 1663 | 0.030 |
Why?
| Regression Analysis | 1 | 2018 | 978 | 0.030 |
Why?
| Heart | 1 | 2020 | 635 | 0.030 |
Why?
| Radiotherapy, Adjuvant | 1 | 2016 | 209 | 0.030 |
Why?
| Internationality | 1 | 2016 | 148 | 0.030 |
Why?
| Random Allocation | 1 | 2016 | 343 | 0.030 |
Why?
| Robotic Surgical Procedures | 1 | 2017 | 109 | 0.030 |
Why?
| Antibodies, Neoplasm | 1 | 2015 | 35 | 0.030 |
Why?
| Biopsy, Large-Core Needle | 1 | 2014 | 13 | 0.030 |
Why?
| Myocardium | 1 | 2020 | 965 | 0.030 |
Why?
| Analysis of Variance | 1 | 2017 | 1269 | 0.030 |
Why?
| Bone Marrow | 1 | 2015 | 267 | 0.030 |
Why?
| Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| Receptor Cross-Talk | 1 | 2013 | 21 | 0.030 |
Why?
| Receptor, Notch1 | 1 | 2013 | 61 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1476 | 0.030 |
Why?
| Metabolic Clearance Rate | 1 | 2012 | 103 | 0.020 |
Why?
| Gene Silencing | 1 | 2013 | 185 | 0.020 |
Why?
| Psychiatric Status Rating Scales | 1 | 2014 | 528 | 0.020 |
Why?
| Transcriptome | 1 | 2018 | 881 | 0.020 |
Why?
| Needs Assessment | 1 | 2014 | 359 | 0.020 |
Why?
| Nausea | 1 | 2012 | 107 | 0.020 |
Why?
| Logistic Models | 1 | 2017 | 1974 | 0.020 |
Why?
| Area Under Curve | 1 | 2012 | 279 | 0.020 |
Why?
| Vomiting | 1 | 2012 | 126 | 0.020 |
Why?
| Diarrhea | 1 | 2012 | 177 | 0.020 |
Why?
| Mice, Nude | 1 | 2013 | 682 | 0.020 |
Why?
| Blotting, Western | 1 | 2013 | 1164 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2012 | 751 | 0.020 |
Why?
| Fatigue | 1 | 2012 | 317 | 0.020 |
Why?
| Cell Proliferation | 1 | 2017 | 2344 | 0.020 |
Why?
| Time Factors | 1 | 2019 | 6482 | 0.020 |
Why?
| Lung | 1 | 2021 | 3743 | 0.020 |
Why?
| Age Factors | 1 | 2016 | 3103 | 0.020 |
Why?
| Colorado | 1 | 2018 | 4375 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 4892 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1983 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2018 | 5362 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2014 | 5039 | 0.010 |
Why?
|
|
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|